http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017178941-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_afcfc7af43784847a2171ad49795c3c3 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C49-84 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-381 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C49-80 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4402 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C49-82 |
| filingDate | 2017-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_65489a6ac67f9e41137c3b91345b424c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b43b747bb98b02fac11bce5e5c494360 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12ee754dbfa610f9db77ba1602b3ba55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0fecbb1d15e50e41da8f752c7cd626df |
| publicationDate | 2017-10-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2017178941-A |
| titleOfInvention | Composition for inhibiting androgen-dependent or independent prostate cancer cells and pharmaceutical preparation for prostate cancer containing the same |
| abstract | [PROBLEMS] To suppress the activation of androgen receptor, which is used for prostate cancer, is effective in suppressing androgen-dependent or independent growth of prostate cancer, and has an effect even if AR-V7 is expressed. Provided are a composition for suppressing androgen-dependent or independent prostate cancer cells that is effective against an anticancer drug-resistant cell line, and a pharmaceutical preparation for prostate cancer using the same. A composition for inhibiting androgen-dependent or independent prostate cancer cells has the chemical formula (1) [Chemical 1] (X- is a hydrocarbon aromatic ring group or aromatic heterocyclic group, Y 1 -and Y 2 -are both or one is a hydrocarbon aromatic ring group or aromatic heterocyclic group, the other is a hydrogen atom, Z = is a bonded carbon Α, β-saturated or unsaturated represented by an atom or a functional group that forms or forms a ketone group, a thioketone group, an imino group, or an oxime group with an atom, and Y 3 -represents a hydrogen atom, a perhalogeno hydrocarbon group, etc. Including a ketone derivative or a pharmaceutically acceptable salt thereof. A pharmaceutical preparation for prostate cancer contains this composition. [Selection figure] None |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020505357-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114685601-A |
| priorityDate | 2016-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 190.